Merck Pulls Plug On Two Keytruda Late-Stage Studies On Underwhelming Data
Portfolio Pulse from Vandana Singh
Merck & Co Inc (NYSE:MRK) has decided to discontinue two Phase 3 trials involving Keytruda due to underwhelming data. The trials, KEYNOTE-867 and KEYNOTE-630, did not meet their primary endpoints and showed unfavorable risk/benefit profiles. The decision was based on recommendations from independent Data Monitoring Committees.
August 29, 2024 | 2:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Merck has halted two Phase 3 trials for Keytruda due to lack of efficacy and unfavorable risk/benefit profiles. This decision may impact investor sentiment negatively in the short term.
The discontinuation of two major trials for Keytruda, a significant product for Merck, suggests potential challenges in expanding its indications. The lack of efficacy and adverse events leading to trial discontinuation could negatively affect investor confidence and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100